HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its ...

Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge, Massachusetts-based biotech will ...

BridgeBio Pharma, Inc. recently announced a US$550,000,000 fixed-rate senior subordinated unsecured notes offering under Rule 144A, while updating investors on advancing late-stage programs and ...

BridgeBio Pharma, Inc. has announced the pricing of $500 million in convertible senior notes at a 1.75% interest rate, maturing in 2031, in a private offering aimed at qualified institutional buyers.

BridgeBio Pharma plans to offer $500 million in convertible senior notes, aiming to strengthen its financial position and reduce interest expenses. BridgeBio Pharma, Inc. announced plans to offer $500 ...

The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium PALO ALTO, ...

SAN DIEGO--(BUSINESS WIRE)--Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a ...

The Bio-Rad Laboratories Inc.-Bond has a maturity date of 3/15/2032 and offers a coupon of 3.7000%. The payment of the coupon will take place 2,0 times per biannual on the 15.09.. At the current price ...